Skip to content
Inciteful Med

Clinical Trials and the Future of HD Research

Last updated:

Current Huntington's disease research focuses on HTT-lowering therapies, or gene silencing, to reduce the toxic mutant protein in the brain. Through clinical trials and observational studies like Enroll-HD, scientists use biomarkers like NfL to test these root-cause treatments.

Key Takeaways

  • • Researchers are shifting focus toward treating the root cause of Huntington's disease by lowering the mutant huntingtin protein in the brain.
  • • Gene silencing techniques, such as Antisense Oligonucleotides (ASOs) and RNA interference, are actively being tested in clinical trials.
  • • Doctors use predictive tools like the CAP score and NfL biomarker levels to track disease progression and measure if an experimental drug is working.
  • • Enroll-HD is a global observational study that allows patients and family members to contribute to research without taking experimental drugs.

Research into Huntington’s Disease (HD) has moved into an era focused on the “root cause” of the condition. Instead of just treating symptoms, scientists are testing ways to lower the amount of the toxic protein in the brain [1][2].

HTT-Lowering: Silencing the Gene

The most active area of research is HTT-lowering, often called “gene silencing” [3]. These strategies aim to reduce the production of the mutant huntingtin protein (mHTT) [4][5].

  • Antisense Oligonucleotides (ASOs): These are short, synthetic strings of DNA that act like “velcro” to block the instructions for making the toxic protein [3][6]. They are usually delivered via a spinal tap (intrathecal injection) [3].
  • RNA Interference (RNAi): This approach uses a viral vector (a harmless virus) to deliver instructions that tell the cell to “cut up” the toxic genetic message [3][7]. This is often a one-time surgical procedure [3].
  • Allele-Selective vs. Non-Selective: Some trials lower both the healthy and the mutant protein (non-selective), while others target only the mutant version (allele-selective) to preserve the healthy protein’s function [5][8].

Measuring Progress: CAP Score and Biomarkers

Researchers use several tools to predict how the disease might move and if a drug is working:

  • The CAP Score (CAG-Age Product): This is a calculation of your CAG count and your current age [9][10]. It represents the “cumulative exposure” your brain has had to the mutant protein [11][12]. Scientists use this to group people into low, medium, or high-risk categories for clinical trials [13][14].
  • NfL (Neurofilament Light Chain): This is a protein that leaks into the blood or spinal fluid when brain cells are damaged [15][16]. Measuring NfL helps researchers see if a drug is protecting brain cells before a patient even notices a change in their symptoms [15].

Recent Updates and Setbacks

Science is a process of learning from both successes and failures.

  • GENERATION HD1 (Roche/Ionis): This large trial of an ASO (tominersen) was stopped early because it did not show the expected benefits and, at high doses, caused some worsening of symptoms [17][18]. However, researchers learned that lower doses might be safer and are now testing this in a new trial called GENERATION HD2 [19][20].
  • AMT-130 (uniQure): This RNAi therapy has shown encouraging early data, suggesting it may stabilize some symptoms and lower NfL levels over 36 months of follow-up [21][22].

How to Get Involved: Enroll-HD

The best way for most families to contribute to research is through Enroll-HD [23].

  • What it is: A worldwide “observational” study. You do not need to take an experimental drug to participate. It simply collects data on symptoms and health once a year to help scientists understand the disease [23][24].
  • Why it matters: This global database helps scientists find participants for new “interventional” trials (drug tests) and helps them understand how HD changes over time [23][25]. Participation is low-burden and open to gene carriers (premanifest and manifest) and their family members [24][26].

Frequently Asked Questions

What is an HTT-lowering therapy for Huntington's disease?
HTT-lowering, also known as gene silencing, aims to reduce the production of the toxic mutant huntingtin protein in the brain. Researchers use techniques like Antisense Oligonucleotides (ASOs) or RNA interference to block the genetic instructions that create this protein.
What is the difference between allele-selective and non-selective treatments?
Non-selective treatments lower both the healthy and the mutant huntingtin proteins in the brain. In contrast, allele-selective therapies are designed to target only the mutant version, which aims to preserve the normal, healthy functions of the non-mutated protein.
How is the CAP score used in Huntington's disease research?
The CAP score calculates your age and CAG repeat count to estimate your brain's cumulative exposure to the mutant protein over your lifetime. Scientists use this score to predict disease progression and determine if you are eligible for specific clinical trials.
What does the NfL biomarker tell doctors about HD?
Neurofilament Light Chain (NfL) is a protein that leaks into your blood or spinal fluid when brain cells are damaged. Measuring NfL levels helps researchers determine if an experimental drug is successfully protecting brain cells, often before you even notice a change in symptoms.
What is Enroll-HD and how can I participate?
Enroll-HD is a worldwide observational study that collects yearly health data from HD families to help scientists better understand the disease. You do not need to take experimental drugs to join, and participation is open to gene carriers as well as their family members.

Questions for Your Doctor

  • • Based on my CAG repeat and age, what is my current CAP score, and how does it affect my eligibility for clinical trials?
  • • Can you explain the difference between 'allele-selective' and 'non-selective' huntingtin-lowering therapies?
  • • Is there a local center where I can enroll in the Enroll-HD observational study?
  • • Are we measuring my Neurofilament Light chain (NfL) levels, and if so, what do they tell us about my disease progression?
  • • How did the setbacks in the GENERATION HD1 trial change the way you think about current and future research?

Questions for You

  • • How do I feel about participating in medical research—am I comfortable with observational studies (just data) or am I looking for interventional trials (testing new drugs)?
  • • How much do I want to know about 'biomarkers' like NfL that might predict changes before they happen?
  • • What are my priorities for future treatments—am I more concerned with physical symptoms or cognitive/mood changes?
  • • Who is my 'research partner' (family member or friend) who can help me keep track of study appointments?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.

    Tong H, Yang T, Xu S, et al.

    International journal of molecular sciences 2024; (25(7)) doi:10.3390/ijms25073845.

    PMID: 38612657
  2. 2

    Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

    Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, et al.

    The Lancet. Neurology 2022; (21(7)):645-658 doi:10.1016/S1474-4422(22)00121-1.

    PMID: 35716694
  3. 3

    Therapeutic strategies for Huntington's disease.

    Estevez-Fraga C, Flower MD, Tabrizi SJ

    Current opinion in neurology 2020; (33(4)):508-518 doi:10.1097/WCO.0000000000000835.

    PMID: 32657893
  4. 4

    An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment.

    Yao JY, Liu T, Hu XR, et al.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024; (180()):117557 doi:10.1016/j.biopha.2024.117557.

    PMID: 39405896
  5. 5

    Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT.

    Iwamoto N, Liu Y, Frank-Kamenetsky M, et al.

    Molecular therapy. Nucleic acids 2024; (35(3)):102246 doi:10.1016/j.omtn.2024.102246.

    PMID: 39027419
  6. 6

    An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.

    Keller CG, Shin Y, Monteys AM, et al.

    Nature communications 2022; (13(1)):1150 doi:10.1038/s41467-022-28653-6.

    PMID: 35241644
  7. 7

    Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.

    Komatsu H

    Frontiers in cellular neuroscience 2021; (15()):785703 doi:10.3389/fncel.2021.785703.

    PMID: 34899193
  8. 8

    The effects of huntingtin-lowering: what do we know so far?

    Kaemmerer WF, Grondin RC

    Degenerative neurological and neuromuscular disease 2019; (9()):3-17 doi:10.2147/DNND.S163808.

    PMID: 30881191
  9. 9

    Standardizing the CAP Score in Huntington's Disease by Predicting Age-at-Onset.

    Warner JH, Long JD, Mills JA, et al.

    Journal of Huntington's disease 2022; (11(2)):153-171 doi:10.3233/JHD-210475.

    PMID: 35466943
  10. 10

    Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease.

    Liu CF, Younes L, Tong XJ, et al.

    Brain communications 2023; (5(5)):fcad214 doi:10.1093/braincomms/fcad214.

    PMID: 37744022
  11. 11

    Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.

    Parkin GM, Corey-Bloom J, Snell C, et al.

    Scientific reports 2023; (13(1)):1034 doi:10.1038/s41598-023-28019-y.

    PMID: 36658243
  12. 12

    Skin Tau Quantification as a Novel Biomarker in Huntington's Disease.

    Ruiz-Barrio I, Vázquez-Oliver A, Puig-Davi A, et al.

    Movement disorders : official journal of the Movement Disorder Society 2024; (39(11)):2067-2074 doi:10.1002/mds.29989.

    PMID: 39192729
  13. 13

    MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.

    Reed ER, Latourelle JC, Bockholt JH, et al.

    Neurology 2018; (90(4)):e264-e272 doi:10.1212/WNL.0000000000004844.

    PMID: 29282329
  14. 14

    How Early Does Anosognosia Begin in Huntington's Disease?

    Bagga K, Xu A, Hall A, et al.

    Movement disorders clinical practice 2025; (12(11)):1942-1946 doi:10.1002/mdc3.70342.

    PMID: 40888179
  15. 15

    Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.

    Caron NS, Byrne LM, Lemarié FL, et al.

    Translational neurodegeneration 2024; (13(1)):50 doi:10.1186/s40035-024-00443-8.

    PMID: 39380076
  16. 16

    Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease.

    Caron NS, Fan J, Ma D, et al.

    Molecular therapy. Nucleic acids 2025; (36(4)):102710 doi:10.1016/j.omtn.2025.102710.

    PMID: 41049089
  17. 17

    Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials.

    Imbimbo BP, Triaca V, Imbimbo C, Nisticò R

    Neural regeneration research 2023; (18(8)):1679-1683 doi:10.4103/1673-5374.363185.

    PMID: 36751779
  18. 18

    Therapeutic targeting of Huntington's disease: Molecular and clinical approaches.

    Kumar D, Hasan GM, Islam A, Hassan MI

    Biochemical and biophysical research communications 2023; (655()):18-24 doi:10.1016/j.bbrc.2023.02.075.

    PMID: 36913762
  19. 19

    Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients.

    Yamamoto Y, Silber Baumann HE, Björnsson M, et al.

    British journal of clinical pharmacology 2025; doi:10.1002/bcp.70367.

    PMID: 41287980
  20. 20

    Huntington's Disease Clinical Trials Corner: August 2023.

    Estevez-Fraga C, Tabrizi SJ, Wild EJ

    Journal of Huntington's disease 2023; (12(2)):169-185 doi:10.3233/JHD-239001.

    PMID: 37483021
  21. 21

    Huntington's disease clinical trials update: October 2025.

    Farag M, Tabrizi SJ, Wild EJ

    Journal of Huntington's disease 2026; (15(1)):156-166 doi:10.1177/18796397251399751.

    PMID: 41295902
  22. 22

    AMT-130 gene therapy: a promising disease-modifying approach for Huntington's disease.

    Mwape C, Qureshi AA, Saeed MZ, et al.

    Annals of medicine and surgery (2012) 2026; (88(1)):1144-1145 doi:10.1097/MS9.0000000000004574.

    PMID: 41497150
  23. 23

    Enroll-HD: An Integrated Clinical Research Platform and Worldwide Observational Study for Huntington's Disease.

    Sathe S, Ware J, Levey J, et al.

    Frontiers in neurology 2021; (12()):667420 doi:10.3389/fneur.2021.667420.

    PMID: 34484094
  24. 24

    Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease.

    Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al.

    Movement disorders clinical practice 2017; (4(2)):212-224 doi:10.1002/mdc3.12388.

    PMID: 30363395
  25. 25

    Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.

    Langbehn DR, Fine EM, Meier A, Hersch S

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(5)):1040-1046 doi:10.1002/mds.28944.

    PMID: 35170086
  26. 26

    Genetic and Environmental Contributors to Neurodegeneration: An Exploration of the Effects of Alcohol on Clinical Features of Huntington's Disease Using the Enroll-HD Global Platform.

    Symonds AL, Macerollo A, Foy K, et al.

    International journal of environmental research and public health 2021; (18(10)) doi:10.3390/ijerph18105113.

    PMID: 34065918

This page discusses experimental therapies and clinical trials for Huntington's disease for educational purposes only. Always consult your neurologist before making decisions about participating in medical research.

Stay up to date

Get notified when new research about Huntington disease is published.

No spam. Unsubscribe anytime.